PUBLISHER: The Business Research Company | PRODUCT CODE: 2127331
PUBLISHER: The Business Research Company | PRODUCT CODE: 2127331
Glucagon-like peptide-1 (GLP-1) companion food and nutrition refers to specially formulated dietary products and nutritional approaches created to complement and improve the effectiveness of GLP-1-based treatments for weight management and metabolic health. These foods and nutritional formulations are generally designed to promote satiety, maintain stable blood glucose levels, and support the physiological effects of GLP-1 hormones.
The primary product types of glucagon-like peptide-1 (GLP-1) companion food and nutrition include high-protein foods, glucagon-like peptide-1 optimized meal kits, nutritional supplements, functional beverages, and low-calorie snacks. High-protein foods are nutritional products developed with increased protein content to promote satiety, preserve muscle mass, and support balanced nutrition. These offerings are intended for consumers such as glucagon-like peptide-1 drug users, individuals seeking weight management, diabetic patients, and general wellness consumers. They emphasize formulations including satiety support products, muscle maintenance products, micronutrient-enhanced products, hydration support products, and digestive comfort products, and are distributed through retail pharmacies, e-commerce platforms, specialty health stores, and direct-to-consumer channels.
Tariffs are influencing the glucagon-like peptide-1 (GLP-1) companion food and nutrition market by increasing the cost of imported specialty ingredients, functional food additives, and nutritional formulation technologies used to develop metabolic health-focused products. This is placing cost pressure on segments such as functional beverages and nutritional supplements, where supply chains for bioactive compounds and protein isolates depend heavily on international trade. Regions including Asia-Pacific and Europe are facing increased pricing challenges due to their reliance on imported health ingredients and formulation equipment. However, tariffs are also fostering localized food production, regional procurement of functional ingredients, and innovation within domestic nutraceutical manufacturing ecosystems.
The glucagon-like peptide-1 (glp) companion food and nutrition market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide-1 (glp) companion food and nutrition market statistics, including glucagon-like peptide-1 (glp) companion food and nutrition industry global market size, regional shares, competitors with a glucagon-like peptide-1 (glp) companion food and nutrition market share, detailed glucagon-like peptide-1 (glp) companion food and nutrition market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide-1 (glp) companion food and nutrition industry. This glucagon-like peptide-1 (glp) companion food and nutrition market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The glucagon-like peptide-1 (GLP) companion food and nutrition market size has grown exponentially in recent years. It will grow from $3.2 billion in 2025 to $4.14 billion in 2026 at a compound annual growth rate (CAGR) of 29.2%. The growth in the historic period can be attributed to rising prevalence of obesity and type 2 diabetes globally, increasing adoption of pharmacological weight management therapies, growth in functional food and dietary supplement industry, early clinical success of GLP-1 receptor agonist drugs, increasing consumer awareness of metabolic health management.
The glucagon-like peptide-1 (GLP) companion food and nutrition market size is expected to see exponential growth in the next few years. It will grow to $11.66 billion in 2030 at a compound annual growth rate (CAGR) of 29.6%. The growth in the forecast period can be attributed to expansion of GLP-1 drug adoption for weight and diabetes care, rising demand for personalized nutrition and precision diet planning, growth of digital health and nutrition tracking platforms, increasing integration of food-tech and biotech innovations, expansion of preventive healthcare and metabolic wellness programs. Major trends in the forecast period include personalized metabolic nutrition planning for GLP-1 therapy support, satiety-enhancing functional food formulations with appetite regulation focus, low glycemic index meal systems designed for glucose stabilization, microbiome optimized dietary interventions for weight management support, protein enriched and nutrient dense GLP-1 companion diets for muscle preservation.
The increasing rate of obesity is expected to accelerate the growth of the glucagon-like peptide-1 (GLP) companion food and nutrition market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat that can adversely affect health and elevate the risk of diseases such as diabetes, cardiovascular disease, and hypertension. The rising prevalence of obesity is mainly driven by unhealthy eating habits, including excessive consumption of calorie-dense, processed, and sugary foods, along with insufficient levels of physical activity. Glucagon-like peptide-1 (GLP) companion food and nutrition contributes to obesity management by complementing GLP-1-based weight-loss therapies with high-protein and high-fiber nutritional formulations that promote satiety, reduce excessive food intake, and help maintain lean muscle mass during calorie restriction. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, between 2023 and 2024, an estimated 64.5% of adults aged 18 years and above in England were overweight or living with obesity, compared with 64.0% during 2022 to 2023. Therefore, the increasing rate of obesity is driving the growth of the oral glucagon-like peptide-1 (GLP) companion food and nutrition market.
Key companies operating in the glucagon-like peptide-1 (GLP) companion food and nutrition market are focusing on developing innovative nutritional support solutions, such as protein and fiber-enriched companion food combinations, to improve dietary balance, prevent muscle loss, and address potential nutrient deficiencies associated with GLP-1-based weight-loss therapies. Protein and fiber-enriched companion food combinations are specially formulated food products that contain increased levels of protein and dietary fiber to support nutrition, promote satiety, and improve digestive health, particularly for individuals with reduced food intake or specific nutritional requirements. For example, in February 2024, Herbalife Ltd., a US-based nutrition and wellness company, launched Herbalife GLP-1 Nutrition Companion, a range of food and supplement product combinations designed to support individuals using GLP-1 and other weight-loss medications. The product range includes protein shake-based formulations and fiber-enriched nutrition blends aimed at helping users fulfill daily nutritional needs while supporting muscle preservation and digestive health. The solution also incorporates community-based nutritional guidance through distributors to promote healthier eating practices during and after weight-loss treatment, supporting long-term lifestyle improvements beyond medication use.
In March 2023, WeightWatchers International Inc., a US-based wellness company, acquired Sequence Weekend Health Inc. for $132 million. Through this acquisition, WeightWatchers aims to transition from a traditional diet and weight-loss provider into a modern clinical weight-management platform. The company focuses on integrating prescription obesity treatments, including Glucagon Like Peptide-1 medications, through telehealth services and digital support tools. Sequence Weekend Health Inc. is a US-based clinical weight-loss and obesity care company that provides GLP-1 companion nutrition and weight-management support programs, including personalized nutrition guidance, protein and hydration targets, dietitian support, behavioral coaching, recipes, and GLP-1-specific lifestyle programs designed to complement GLP-1 medications.
Major companies operating in the glucagon-like peptide-1 (glp) companion food and nutrition market report are Nestle S.A., Danone S.A., Arla Foods amba, Glanbia plc, Herbalife Ltd., BellRing Brands Inc., The Simply Good Foods Company
North America was the dominating region in the glucagon-like peptide-1 (GLP) companion food and nutrition market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the glucagon-like peptide-1 (GLP) companion food and nutrition market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the glucagon-like peptide-1 (GLP) companion food and nutrition market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The glucagon-like peptide-1 (GLP) companion food and nutrition market consists of sales of nutrient-dense foods, medically formulated meal replacements, low-calorie snacks, and dietary supplements. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Glucagon-Like Peptide-1 (GLP) Companion Food And Nutrition Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses glucagon-like peptide-1 (glp) companion food and nutrition market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for glucagon-like peptide-1 (glp) companion food and nutrition ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The glucagon-like peptide-1 (glp) companion food and nutrition market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.